The company participates in an interesting niche, with definitive barriers to entry. The industry is currently undergoing a cyclical downturn, but DIBS has notLong-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings power of companies, the competitive dynamics of the industries where they participate, and buy ...

Analyst’s Disclosure:I/we have a beneficial long position in the shares of YARIY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA. It may be structured as such, but it is not f ...

Just over four months have passed since the publication of my last article , "Why Investors Should Watch Teva Despite Regional Risks," and during that time, the Teva Pharmaceutical Industries Limited (NYSE: TEVA ) share priceWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, a ...

Just over four months have passed since the publication of my last article , "Why Investors Should Watch Teva Despite Regional Risks," and during that time, the Teva Pharmaceutical Industries Limited (NYSE: TEVA ) share priceWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, a ...

The Fed cut the policy rate during the last meeting and pre-committed to another two cuts until the end of 2025. This came despite inflation being above the target for yearsAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business r ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end Q3, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have a beneficial long position in the shares of SFIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned i ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end Q3, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have a beneficial long position in the shares of SFIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned i ...

There are two key reasons for this. First off, income investing - while sub-optimal from a total returns perspective - offers a much greater degree of consistency over longAt PropNotes, we focus on finding high-yield investment opportunities for individual investors.With our background in professional Prop Trading, we make complex concepts easy to understand and offer clear, actionable insights to help you achieve better returns.All of the analysis we produce is designed to help you make smart decisions in ...

PresentationFormat of this session is going to be just some brief slides to get us going, and then we'll go into a fireside chat and Q&A. So with that, Olivier?Thanks, everyone, for joining us. We'll kick off our next session. My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team based out of New York. I'm excited to host Repligen Corp for our next session. We're joined by Jason Garland, CFO; and Olivier Loeillot, CEO.Olivier LoeillotPresident, CEO & Director Thank you s ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...